Vitamin E Supplementation Reduces Cardiovascular Events in a Subgroup of Middle-Aged Individuals With Both Type 2 Diabetes Mellitus and the Haptoglobin 2-2 Genotype
Open Access
- 1 February 2008
- journal article
- research article
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 28 (2) , 341-347
- https://doi.org/10.1161/atvbaha.107.153965
Abstract
Objective— Clinical trials of vitamin E have failed to demonstrate a decrease in cardiovascular events. However, these studies did not address possible benefit to subgroups with increased oxidative stress. Haptoglobin (Hp), a major antioxidant protein, is a determinant of cardiovascular events in patients with Type 2 diabetes mellitus (DM). The Hp gene is polymorphic with 2 common alleles, 1 and 2. The Hp 2 allelic protein product provides inferior antioxidant protection compared with the Hp 1 allelic product. We sought to test the hypothesis that vitamin E could reduce cardiovascular events in DM individuals with the Hp 2-2 genotype, a subgroup that comprises 2% to 3% of the general population.Keywords
This publication has 35 references indexed in Scilit:
- Vitamin E in the Primary Prevention of Cardiovascular Disease and CancerJAMA, 2005
- Effects of Long-term Vitamin E Supplementation on Cardiovascular Events and CancerJAMA, 2005
- Is There Any Hope for Vitamin E?Published by American Medical Association (AMA) ,2005
- Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trialsThe Lancet, 2003
- Effects of Hormone Replacement Therapy and Antioxidant Vitamin Supplements on Coronary Atherosclerosis in Postmenopausal WomenJAMA, 2002
- MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trialPublished by Elsevier ,2002
- Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general PracticeThe Lancet, 2001
- Vitamin E Supplementation and Cardiovascular Events in High-Risk PatientsNew England Journal of Medicine, 2000
- Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trialThe Lancet, 1999
- Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS)The Lancet, 1996